Rothe M - Search Results

1

Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma.

Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt KH, Benckert J. Leineweber CG, et al. Among authors: rothe m. Front Pharmacol. 2023 Mar 3;14:1124214. doi: 10.3389/fphar.2023.1124214. eCollection 2023. Front Pharmacol. 2023. PMID: 36937889 Free PMC article.

2

Humanization of the Reaction Specificity of Mouse Alox15b Inversely Modified the Susceptibility of Corresponding Knock-In Mice in Two Different Animal Inflammation Models.

Schäfer M, Reisch F, Labuz D, Machelska H, Stehling S, Püschel GP, Rothe M, Heydeck D, Kuhn H. Schäfer M, et al. Among authors: rothe m. Int J Mol Sci. 2023 Jul 3;24(13):11034. doi: 10.3390/ijms241311034. Int J Mol Sci. 2023. PMID: 37446212 Free PMC article.

3

Functional Characterization of Transgenic Mice Overexpressing Human 15-Lipoxygenase-1 (ALOX15) under the Control of the aP2 Promoter.

Heydeck D, Ufer C, Kakularam KR, Rothe M, Liehr T, Poulain P, Kuhn H. Heydeck D, et al. Among authors: rothe m. Int J Mol Sci. 2023 Mar 2;24(5):4815. doi: 10.3390/ijms24054815. Int J Mol Sci. 2023. PMID: 36902243 Free PMC article.

4

Fatty acid desaturase 2 determines the lipidomic landscape and steroidogenic function of the adrenal gland.

Witt A, Mateska I, Palladini A, Sinha A, Wölk M, Harauma A, Bechmann N, Pamporaki C, Dahl A, Rothe M, Kopaliani I, Adolf C, Riester A, Wielockx B, Bornstein SR, Kroiss M, Peitzsch M, Moriguchi T, Fedorova M, Grzybek M, Chavakis T, Mirtschink P, Alexaki VI. Witt A, et al. Among authors: rothe m. Sci Adv. 2023 Jul 21;9(29):eadf6710. doi: 10.1126/sciadv.adf6710. Epub 2023 Jul 21. Sci Adv. 2023. PMID: 37478183 Free PMC article.

5

15-keto-Prostaglandin E₂ exhibits bioactive role by modulating glomerular cytoarchitecture through EP2/EP4 receptors.

Kourpa A, Kaiser-Graf D, Sporbert A, Philippe A, Catar R, Rothe M, Mangelsen E, Schulz A, Bolbrinker J, Kreutz R, Panáková D. Kourpa A, et al. Among authors: rothe m. Life Sci. 2022 Dec 1;310:121114. doi: 10.1016/j.lfs.2022.121114. Epub 2022 Oct 20. Life Sci. 2022. PMID: 36273629 Free article.

6

Serotonin-induced stereospecific formation and bioactivity of the eicosanoid 17,18-epoxyeicosatetraenoic acid in the regulation of pharyngeal pumping of C. elegans.

Zhou Y, Rothe M, Schunck WH, Ruess L, Menzel R. Zhou Y, et al. Among authors: rothe m. Biochim Biophys Acta Mol Cell Biol Lipids. 2023 May;1868(5):159304. doi: 10.1016/j.bbalip.2023.159304. Epub 2023 Mar 11. Biochim Biophys Acta Mol Cell Biol Lipids. 2023. PMID: 36914111

7

Corrigendum to "Hemodialysis and Biotransformation of Erythrocyte Epoxy Fatty Acids in Peripheral Tissue".

Liu T, Dogan I, Rothe M, Kunz JV, Knauf F, Gollasch M, Luft FC, Gollasch B. Liu T, et al. Among authors: rothe m. Prostaglandins Leukot Essent Fatty Acids. 2023 Dec;198-199:102521. doi: 10.1016/j.plefa.2022.102521. Epub 2022 Dec 7. Prostaglandins Leukot Essent Fatty Acids. 2023. PMID: 36494277 No abstract available.

8

Studies in Zebrafish and Rat Models Support Dual Blockade of EP2 and EP4 (Prostaglandin E₂ Receptors Type 2 and 4) for Renoprotection in Glomerular Hyperfiltration and Albuminuria.

Kourpa A, Schulz A, Mangelsen E, Kaiser-Graf D, Koppers N, Stoll M, Rothe M, Bader M, Purfürst B, Kunz S, Gladytz T, Niendorf T, Bachmann S, Mutig K, Bolbrinker J, Panáková D, Kreutz R. Kourpa A, et al. Among authors: rothe m. Hypertension. 2023 Apr;80(4):771-782. doi: 10.1161/HYPERTENSIONAHA.122.20392. Epub 2023 Jan 30. Hypertension. 2023. PMID: 36715011

9

Response to Smith and Shaw "Response to "Safety of dermatologic medications in pregnancy and lactation: An update - Part 1: Pregnancy & Part 2: Lactation"".

McMullan P, Yaghi M, Truong TM, Rothe M, Murase J, Grant-Kels JM. McMullan P, et al. Among authors: rothe m. J Am Acad Dermatol. 2024 Apr 12:S0190-9622(24)00628-5. doi: 10.1016/j.jaad.2024.04.017. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38614252 No abstract available.

10

Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Sahai V, Rothe M, Mangat PK, Garrett-Mayer E, Suhag V, Dib EG, Mehmi I, Kadakia KC, Pisick E, Duvivier HL, Le P, Li R, Michelin DP, Wilcox RE, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sahai V, et al. Among authors: rothe m. JCO Precis Oncol. 2024 Apr;8:e2300527. doi: 10.1200/PO.23.00527. JCO Precis Oncol. 2024. PMID: 38603652

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

427 results

Search Page